The LLC have announced that they have entered into a collaboration that quickly provides a Gallus with expanded GMP biomanufacturing capacity by leveraging they key advantages of the turnkey Xcellerex FlexFactory GMP manufacturing platform suite. The strategic collaboration will provide Gallus with the world – class, scalable, flexible and the cost-efficient manufacturing and the laboratory technology to expand its contract manufacturing business. This partnership will provide Xcellerex’s customers unprecedented access to a commercial. The Gallus with the world class, scalable, flexible and cost-efficient manufacturing and the laboratory technology to expand its contract manufacturing and the cost efficient manufacturing and laboratory technology Xcellerex’s customers unprecedented access to a commercial. The Gallus is acquiring a several Xcellerex bio production systems for the new suites and the laboratories at its existing manufacturing suite.
The Gallus is acquiring a several Xcellerex bioproduction systems for the new suites and the laboratories at its existing manufacturing facility. This is with the single-use XDR bioreactors to quickly expand capabilities in an existing commercial manufacturing suite. The Gallus acquiring small scale 10L bioreactors for its expanded development laboratory and a turnkey FlexFactory cGMP manufacturing line with the XDR single-use bioreactors up to 2000 liters scale for the clinical supply. The rapid capacity expansion with the single-use technology is not only augments Gallus to offer more services and options to its customers but also augments Gallus existing multi-suite commercial capacity with Gallus will provide their customers with the access to Gallus established biomanufacturing expertise in a world-class facility that has been inspected and approved by all major regulatory authorities.
The Gallus has a unique contract manufacturing business model that enables people to respond the clients changing capacity needs quickly and to achieved rapid, high quality production at a competitive price. The partnership with Xcellerex allows people to leverage their single use biomanufacturing platform. The strategic investment that rapidly provides people with an additional manufacturing capacity and the scale-up capabilities to deliver development, clinical and the commercial products and services. The first manufacturing suite will be in place by the end of 2011. The suites can be added to meet specific customer needs this is within the existing facility at their site in St. Louis.
The facility is currently producing two commercial products that are approved globally. The company’s business model includes a condominium concept that allows a client to virtually-own a manufacturing suite for its process development and production needs. This novel approach provides clients with the complete flexibility in accessing capacity as needed. Gallus is the capitalizing on the etraordinary flexibility affordable by the FlexFactory along with the extensive manufacturing experience of its team, to provide innovative solutions for the establishment as well as the development stage biopharmaceutical companies.
REFERENCE:
http://www.pharmpro.com/news/2011/05/business-Xcellerex-and-Gallus-BioPharmaceuticals-Announce-Biomanufacturing-Collaboration/
